U.S. markets closed

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1500+0.0600 (+1.47%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.0900
Open4.1000
Bid4.1600 x 1100
Ask4.1900 x 1000
Day's Range3.5500 - 4.1900
52 Week Range2.5500 - 9.0000
Volume2,967,290
Avg. Volume5,317,990
Market Cap122.173M
Beta (5Y Monthly)2.82
PE Ratio (TTM)N/A
EPS (TTM)-2.0570
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
    Zacks

    Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know

    Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.

  • Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
    GlobeNewswire

    Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference

    DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021. Investors interested in arranging a virtual meeting with the Company’s management on Wednesday, March 17, should contact the ROTH conference coordinator or brandon.weiner@westwicke.com. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Investor ContactPeter VozzoWestwicke, an ICR Company Office: 443-213-0505Cell: 443-377-4767peter.vozzo@westwicke.com

  • Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
    Zacks

    Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

    Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.